search
Back to results

Self-Advocacy Serious Game in Advanced Cancer

Primary Purpose

Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Strong Together serious game
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Ovarian Cancer Stage III focused on measuring Self-advocacy, Advanced cancer, Serious games, Self-management

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female

    -≥18 years

  • Diagnosed with Stage III or IV gynecological or Stage IV breast cancer within the past 3 months being treated with non-curative intent
  • Have at least a 6-month life expectancy (as determined by their oncologist)
  • Eastern Cooperative Oncology Group performance score of 0 to 2 (per health record or oncologist)
  • Able to read and write in English

Exclusion Criteria:

  • On hospice at the time of recruitment
  • Impaired cognition (per health record)
  • Other active, unstable mental health disorder

Sites / Locations

  • University of Pittsburgh Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Serious game intervention

Enhanced care as usual

Arm Description

Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.

If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.

Outcomes

Primary Outcome Measures

Number of participants who engage in at least 8 out of the 12 serious game sessions
We will calculate the number of participants in the intervention group who complete two-thirds (66.7%) of the intervention sessions as a measure of intervention feasibility. We will accept that we achieved adequate feasibility if at least 75% of participants engage in at least eight out of the twelve serious game sessions.
Number of participants who find the intervention acceptable based on ratings of the Post Study System Usability Questionnaire and qualitative interviews.
We will accept that we achieved adequate acceptability if at least 80% of participants find the intervention acceptable based on the Post Study System Usability Questionnaire scores and if no issues are raised during the qualitative interviews and feedback that cannot be revised prior to the future trial.

Secondary Outcome Measures

Change in patient self-advocacy as assessed by the Female Self-Advocacy in Cancer Survivorship Scale.
We anticipate that self-advocacy scores will increase (improve) among participants in the intervention group compared to the enhanced care as usual group.
Change in symptom burden as assessed by the MD Anderson Symptom Inventory scale.
We anticipate that symptom burden scores will decrease (improve) among participants in the intervention group compared to the enhanced care as usual group.
Change in healthcare utilization as assessed by participants' number of hospital admissions, emergency room visits, and primary care visits in the past three months.
We anticipate that the frequency of healthcare utilization will decrease (improve) among participants in the intervention group compared to the enhanced care as usual group.
Change in quality of life as assessed by the Functional Assessment of Cancer Therapy-General scale.
We anticipate that quality of life will increase (improve) among participants in the intervention group compared to the enhanced care as usual group.

Full Information

First Posted
November 3, 2017
Last Updated
July 3, 2023
Sponsor
University of Pittsburgh
search

1. Study Identification

Unique Protocol Identification Number
NCT03339765
Brief Title
Self-Advocacy Serious Game in Advanced Cancer
Official Title
Piloting a Serious Game to Improve Self-Advocacy Among Women With Advanced Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
December 13, 2018 (Actual)
Primary Completion Date
March 18, 2021 (Actual)
Study Completion Date
March 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Self-advocacy, defined as the ability of a patient to get her needs and priorities met in the face of a challenge, is an essential skill but not all women with advanced cancer are able to do it. We want to instruct women with advanced cancer who have low self-advocacy to self-advocate for their health and well-being. We will test a new "serious game" or video program that teaches self-advocacy skills through interactive, situation-based activities. The goal of the Strong Together serious game is to engage participants in challenges commonly experienced by women with advanced cancer, offer them choices to self-advocate or not, and directly show them the health and social benefits of self-advocating and the negative consequences of not self-advocating. Through engaging in the Strong Together program, participants vicariously learn the essential skills of self-advocacy, understand the downstream effects of using or not using these skills, and learn distinct behaviors that they can then use to address their own challenges.
Detailed Description
Background: When faced with the challenges of advanced cancer, women must advocate (or stand up) for their needs and priorities. However, there are no interventions to promote self-advocacy among female patients with advanced cancer. Preliminary work has developed a theoretically-based, psychometrically-strong measure of self-advocacy (the Female Self-Advocacy in Cancer Survivorship (FSACS) Scale) and demonstrated correlations with symptom burden and healthcare utilization. Serious games offer a novel mechanism by which to deliver interactive, engaging health education that links users' choices to consequences so that users learn a desired skill. The fully-automated Strong Together self-advocacy serious game may allow women with advanced cancer to learn self-advocacy skills and therefore improve their health outcomes. Objective/Hypothesis: The purpose of this pilot randomized controlled trial (RCT) is to evaluate the feasibility, acceptably, and preliminary efficacy of the Strong Together serious game. Specific Aims: Specific Aim 1: To evaluate the feasibility and acceptability of the 3-month Strong Together intervention. Benchmark 1: At least 75% of participants will engage in at least 8 out of the 12 serious game sessions. Benchmark 2: At least 80% of participants will find the intervention acceptable based on ratings of perceived satisfaction and ease of use, as well as feedback from qualitative exit interviews. Specific Aim 2: To explore the differences in self-advocacy and symptom burden between groups over time. • Research Question: Do patients who receive the intervention report improved self-advocacy and lower symptom burden compared to those assigned to enhanced care as usual? Study Design: This pilot RCT will recruit (N=84) women from cancer clinics at the University of Pittsburgh Medical Center. Eligibility criteria include: female; age ≥ 18 years; diagnosis of Stage III or IV gynecological or Stage IV breast cancer within the past 3 months; 6-month prognosis; Eastern Cooperative Oncology Group score of 0-1; and ability to read and write in English. Measures will be collected at baseline, 3 months, and 6 months. Randomization (2:1) will occur to the 3-month Strong Together intervention group or the enhanced care as usual group. Feasibility will be assessed by calculating percentages of the intervention's dosage, engagement, recruitment, retention, and data completion. Acceptability will be assessed through exit interviews and an acceptability scale. Preliminary efficacy will be measured by exploring differences in self-advocacy and symptom burden scores and calculating point and interval estimates between the groups at 3 and 6 months. Cancer Relevance: This study represents a unique opportunity to address the lack of self-advocacy interventions, reduce the risks of women with low self-advocacy, and guide an adequately-powered RCT to educate women with advanced cancer to self-advocate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV, Cervical Cancer Stage IIIB, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB, Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Vulvar Cancer, Stage III, Vulvar Cancer, Stage IV, Vaginal Cancer Stage III, Vaginal Cancer Stage IVA, Vaginal Cancer Stage IVB
Keywords
Self-advocacy, Advanced cancer, Serious games, Self-management

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
78 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Serious game intervention
Arm Type
Experimental
Arm Description
Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
Arm Title
Enhanced care as usual
Arm Type
No Intervention
Arm Description
If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
Intervention Type
Behavioral
Intervention Name(s)
Strong Together serious game
Intervention Description
The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
Primary Outcome Measure Information:
Title
Number of participants who engage in at least 8 out of the 12 serious game sessions
Description
We will calculate the number of participants in the intervention group who complete two-thirds (66.7%) of the intervention sessions as a measure of intervention feasibility. We will accept that we achieved adequate feasibility if at least 75% of participants engage in at least eight out of the twelve serious game sessions.
Time Frame
3 months
Title
Number of participants who find the intervention acceptable based on ratings of the Post Study System Usability Questionnaire and qualitative interviews.
Description
We will accept that we achieved adequate acceptability if at least 80% of participants find the intervention acceptable based on the Post Study System Usability Questionnaire scores and if no issues are raised during the qualitative interviews and feedback that cannot be revised prior to the future trial.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Change in patient self-advocacy as assessed by the Female Self-Advocacy in Cancer Survivorship Scale.
Description
We anticipate that self-advocacy scores will increase (improve) among participants in the intervention group compared to the enhanced care as usual group.
Time Frame
Baseline, 3 months, and 6 months
Title
Change in symptom burden as assessed by the MD Anderson Symptom Inventory scale.
Description
We anticipate that symptom burden scores will decrease (improve) among participants in the intervention group compared to the enhanced care as usual group.
Time Frame
Baseline, 3 months, and 6 months
Title
Change in healthcare utilization as assessed by participants' number of hospital admissions, emergency room visits, and primary care visits in the past three months.
Description
We anticipate that the frequency of healthcare utilization will decrease (improve) among participants in the intervention group compared to the enhanced care as usual group.
Time Frame
Baseline, 3 months, and 6 months
Title
Change in quality of life as assessed by the Functional Assessment of Cancer Therapy-General scale.
Description
We anticipate that quality of life will increase (improve) among participants in the intervention group compared to the enhanced care as usual group.
Time Frame
Baseline, 3 months, and 6 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Inclusion criteria are based on cancer diagnoses which primarily occur in women (gynecological and breast cancer).
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female -≥18 years Diagnosed with Stage III or IV gynecological or Stage IV breast cancer within the past 3 months being treated with non-curative intent Have at least a 6-month life expectancy (as determined by their oncologist) Eastern Cooperative Oncology Group performance score of 0 to 2 (per health record or oncologist) Able to read and write in English Exclusion Criteria: On hospice at the time of recruitment Impaired cognition (per health record) Other active, unstable mental health disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Teresa H Thomas, PhD, RN
Organizational Affiliation
University of Pittsburgh School of Nursing
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15261
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Self-Advocacy Serious Game in Advanced Cancer

We'll reach out to this number within 24 hrs